Company Overview

Senti Biosciences Holdings, Inc. is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies using synthetic biology. The company operates primarily in the biotechnology and immuno-oncology sectors, with a strategic emphasis on next-generation programmable medicines designed to improve precision, safety, and therapeutic durability. Its core technology platform centers on proprietary “Gene Circuit” engineering, which enables cells to sense and respond to biological signals in a controlled manner. The company’s primary revenue sources historically have included collaboration agreements, research partnerships, and financing activities, as it remains in the clinical development stage and has not yet established significant commercial product revenue.

Senti Biosciences was founded in 2016 and evolved from advances in synthetic biology and cellular engineering developed by researchers associated with leading academic and scientific institutions. The company became publicly traded through a merger with a special purpose acquisition company in 2022. Senti has positioned itself as a differentiated developer of logic-gated cell therapies, particularly in oncology applications where precision targeting may reduce toxicity associated with conventional CAR-NK and CAR-T therapies. Its lead programs have focused on allogeneic natural killer (NK) cell therapies engineered with synthetic gene circuits intended to selectively target cancer cells while sparing healthy tissue.

Business Operations

Senti Biosciences conducts operations primarily through its integrated research, development, and clinical programs in engineered cell therapies. Its principal business activities are organized around development programs utilizing its proprietary Gene Circuit platform and engineered allogeneic NK cell technologies. The company’s therapeutic pipeline has included candidates targeting hematologic malignancies and solid tumors, with development efforts focused on improving selectivity, persistence, and controllability of immune cell therapies. Revenue generation has primarily come from strategic collaborations, licensing arrangements, and research funding rather than commercialized therapeutics.

The company operates principally in the United States, with headquarters in South San Francisco, California, while maintaining relationships with academic collaborators, manufacturing providers, and biotechnology partners. Senti controls proprietary synthetic biology technologies related to programmable gene expression, cell-state sensing, and logic-gated therapeutic responses. The company has also relied on contract manufacturing organizations and specialized research partners to support clinical development and production activities. Public disclosures indicate collaboration relationships involving research and development support, although the company remains primarily focused on internally driven pipeline advancement.

Strategic Position & Investments

Senti Biosciences’ strategic direction has centered on advancing programmable cell therapies capable of addressing limitations associated with existing immunotherapies, particularly off-target toxicity and limited tumor specificity. The company has prioritized development of allogeneic NK cell therapies engineered with multi-input gene circuits intended to improve therapeutic precision. Its growth initiatives have included advancing clinical-stage oncology programs, expanding synthetic biology applications, and refining manufacturing scalability for engineered cellular medicines.

The company has invested heavily in its proprietary synthetic biology infrastructure and intellectual property portfolio related to gene circuits, cell signaling regulation, and engineered therapeutic logic systems. Senti’s pipeline strategy has emphasized applications in hematologic cancers and potentially broader immunology or regenerative medicine opportunities. Public filings and investor materials have also indicated strategic cost-management initiatives and pipeline prioritization efforts in response to broader biotechnology capital market conditions. Data regarding long-term commercialization partnerships and large-scale international expansion remains limited based on available public sources.

Geographic Footprint

Senti Biosciences’ primary operational footprint is concentrated in the United States, particularly within the biotechnology ecosystem of California’s Bay Area. The company’s headquarters in South San Francisco places it within a major global biotechnology and life sciences hub, supporting access to research institutions, venture capital networks, manufacturing providers, and clinical collaborators.

While the company’s direct commercial presence outside the United States remains limited due to its clinical-stage status, Senti participates in a globally interconnected biotechnology supply and research environment. Its clinical development activities, scientific collaborations, and investor engagement extend across parts of North America and other international biotechnology markets. The company’s technologies are designed for potential applicability across global oncology treatment markets, although operational influence outside the U.S. remains primarily research-oriented rather than commercial.

Leadership & Governance

Senti Biosciences was co-founded by scientists and biotechnology entrepreneurs focused on advancing synthetic biology applications in medicine. The company’s leadership strategy has emphasized programmable therapeutics, translational science, and disciplined clinical development. Public corporate communications and filings describe a leadership philosophy centered on engineering-driven innovation, scalable therapeutic design, and precision medicine approaches intended to improve the safety profile of cell therapies.

Key executives and leadership figures have included:

• Timothy K. Lu – Co-Founder and former Chief Executive Officer
• Ragini (Rina) Seth – Chief Executive Officer
• Ryan Fletcher – Chief Financial Officer
• Ming Bo Cai – Chief Development Officer
• Jennifer Jarrett – Member of the Board of Directors
• Caroline Loew – Member of the Board of Directors

The company’s governance structure includes a board with biotechnology, pharmaceutical, scientific, and financial expertise intended to support clinical development, capital allocation, and strategic partnerships. Leadership communications in public filings have emphasized advancing differentiated oncology programs while managing operational efficiency and maintaining focus on core platform capabilities.